Literature DB >> 1961042

Therapy of refractory/relapsed acute leukemia with cytosine arabinoside plus tetrahydrouridine (an inhibitor of cytidine deaminase)--a pilot study.

W Kreis1, D R Budman, K Chan, S L Allen, P Schulman, S Lichtman, L Weiselberg, M Schuster, J Freeman, S Akerman.   

Abstract

Thirty two patients with refractory or recurrent acute leukemia or blast crisis of chronic myelocytic leukemia were treated with 1-beta-D-arabinofuranosylcytosine (Ara-C), 100 mg/m2 [group I (n = 15)] or 200 mg/m2 [group II (n = 18)], and tetrahydrouridine (THU) 350 mg/m2, given concurrently as a 3 h continuous intravenous infusion at 12 h interval for eight doses. Two of 13 (15.3%) evaluable patients in group I achieved a complete response, both of whom had acute myelocytic leukemia. In group II, seven of 14 evaluable patients (50%) obtained objective responses--six with complete responses (42.8%) and one with partial response (7%). Myelosuppression was seen in all patients with a median duration of 32.5 days (group I) and 36.3 days (group II), respectively. Non-hematologic toxicity consisted of nausea, vomiting, diarrhea, conjunctivitis, skin rash, hepatocellular toxicity, hemorrhage, and renal toxicity. Pharmacokinetic studies revealed, for group I, mean peak plasma Ara-C levels at 3 h (Cp3h) of 1254 ng/ml, area under the curve (AUC) 4651 ng x h/ml, total body clearance (TBC) 32.65 l/h/m2, renal clearance (RC) 7.04 l/h/m2 with a mean of 12.36% of the injected amount of Ara-C excreted unchanged in urine over the first 24 h. The corresponding mean values for group II are Cp3h 3305 ng/ml, AUC 15080 ng x h/ml, TBC 20.48 l/h/m2, RC 7.02 l/h/m2 and 26.23%. Ara-C 200 mg/m2 combined with THU gave serum Ara-C levels and response rates comparable to those achieved with high dose Ara-C (HiDAC) (greater than or equal to 1 g/m2). Central nervous system toxicity associated with HiDAC was not seen. Pharmacokinetics for uracil arabinoside (Ara-U) in patients treated with Ara-C 200 mg/m2 plus THU, were comparable to values seen with Ara-C for Cp3h, AUC and 24 h urine, amounting to 3160 ng/ml, 21717 ng x h/ml and 23.62% whereas TBC was significantly lower (p less than 0.001) for Ara-U than for Ara-C (3.02 versus 20.48 l/h/m2).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1961042

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  13 in total

1.  Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine.

Authors:  Donald Lavelle; Kestis Vaitkus; Yonghua Ling; Maria A Ruiz; Reda Mahfouz; Kwok Peng Ng; Soledad Negrotto; Nicola Smith; Pramod Terse; Kory J Engelke; Joseph Covey; Kenneth K Chan; Joseph Desimone; Yogen Saunthararajah
Journal:  Blood       Date:  2011-12-07       Impact factor: 22.113

Review 2.  Fetal Hemoglobin Induction by Epigenetic Drugs.

Authors:  Donald Lavelle; James Douglas Engel; Yogen Saunthararajah
Journal:  Semin Hematol       Date:  2018-04-22       Impact factor: 3.851

3.  Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response.

Authors:  W Kreis; M Lesser; D R Budman; Z Arlin; L DeAngelis; P Baskind; E J Feldman; S Akerman
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 4.  Is Monitoring of the Intracellular Active Metabolite Levels of Nucleobase and Nucleoside Analogs Ready for Precision Medicine Applications?

Authors:  Shenjia Huang; Yicong Bian; Chenrong Huang; Liyan Miao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-08-01       Impact factor: 2.569

5.  Cellular pharmacology of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine in the human leukemic cell lines K-562 and U-937.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Authors:  Reda Z Mahfouz; Ania Jankowska; Quteba Ebrahem; Xiaorong Gu; Valeria Visconte; Ali Tabarroki; Pramod Terse; Joseph Covey; Kenneth Chan; Yonghua Ling; Kory J Engelke; Mikkael A Sekeres; Ramon Tiu; Jaroslaw Maciejewski; Tomas Radivoyevitch; Yogen Saunthararajah
Journal:  Clin Cancer Res       Date:  2013-01-03       Impact factor: 12.531

7.  Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin.

Authors:  J H Marsh; W Kreis; B Barile; S Akerman; P Schulman; S L Allen; L C DeMarco; M W Schuster; D R Budman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

8.  Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine.

Authors:  Johan Vande Voorde; Suna Sabuncuoğlu; Sam Noppen; Anders Hofer; Farahnaz Ranjbarian; Steffen Fieuws; Jan Balzarini; Sandra Liekens
Journal:  J Biol Chem       Date:  2014-03-25       Impact factor: 5.157

9.  Cellular pharmacology of a liposomal preparation of N4-hexadecyl-1-beta-D-arabinofuranosylcytosine, a lipophilic derivative of 1-beta-D-arabinofuranosylcytosine.

Authors:  D H Horber; H Schott; R A Schwendener
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

10.  High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.

Authors:  Quteba Ebrahem; Reda Z Mahfouz; Kwok Peng Ng; Yogen Saunthararajah
Journal:  Oncotarget       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.